Latest research on RAD001

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Latest findings

RAD001 was found to almost completely inhibit Estradiol induced proliferation in both control MCF-7 cells as well as Estradiol and androstenedione induced proliferation in MCF-7/Aro cells, suggesting that mTOR signaling is required for estrogen proliferative response in MCF-7 cells. [source, 2004]
Furthermore, combination therapy with Letrozole and RAD001 resulted in increased inhibition of cell proliferation as well as a synergistic effect, even at suboptimal levels of RAD001. [source, 2004]
Based on preclinical studies suggesting that inhibition of mTOR has antiproliferative effects in a variety of cancer models, clinical studies were initiated with two Rapamycin analogs, namely RAD001 and CCI-779. [source, 2004]